Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cinfa Biotech
Pamplona, Navarre, Spain
- Ownership
- Private
- Development stage
- Other
01
Overview
Cinfa Biotech developed Pelmeg (pegfilgrastim), a biosimilar of Neulasta, which was approved by the European Commission in November 2018 and launched in Europe in February 2019[5]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Biosimilarsrecombinant proteins
- Industry
- Biotech
02
Partnerships
Mundipharma (acquired Pelmeg)
Beyond the preview
Go deeper on Cinfa Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cinfa Biotech.